|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000119686 |
Summary for FLVCR2 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000119686 | Gene symbol | FLVCR2 |
| Gene name | FLVCR heme transporter 2 | |
| HGNC | 20105 | |
| Entrez ID | 55640 | |
| Gene type | protein_coding | |
| Synonyms | FLVCR2|FLJ20371|MFSD7C|SLC49A2|CCT | |
| UniProtAcc | Q9UPI3 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for FLVCR2 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| FLVCR2 | 3.46e+02 | 1.59e+00 | 3.49e-01 | 4.55e+00 | 5.35e-06 | 3.42e-05 | BLCA |
| FLVCR2 | 4.28e+02 | -1.09e+00 | 2.22e-01 | -4.91e+00 | 8.92e-07 | 5.18e-06 | STAD |
| FLVCR2 | 1.09e+03 | 1.02e+00 | 1.56e-01 | 6.52e+00 | 6.88e-11 | 4.59e-10 | KIRP |
| FLVCR2 | 4.13e+02 | -2.41e+00 | 4.57e-01 | -5.28e+00 | 1.31e-07 | 1.16e-06 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| FLVCR2 | 1.92e+02 | -1.51e+00 | 2.98e-01 | -5.07e+00 | 3.91e-07 | 3.89e-06 | READ |
Top |
Sex-biased somatic mutation for FLVCR2 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for FLVCR2 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| GBM | cg04001333 | chr14:75579005 | CGI:chr14:75578247-75578759 | promoter,exon,CDS,gene body | 6.56e-01 | 5.27e-01 | 2.50e+00 | 1.24e-02 | 2.78e-02 | 1.29e-01 |
| ESCA | cg04001333 | chr14:75579005 | CGI:chr14:75578247-75578759 | promoter,exon,CDS,gene body | 5.94e-01 | 4.64e-01 | 2.48e+00 | 1.30e-02 | 3.09e-02 | 1.30e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRP | cg04001333 | chr14:75579005 | CGI:chr14:75578247-75578759 | promoter,exon,CDS,gene body | 1.64e-01 | 2.82e-01 | -4.12e+00 | 3.82e-05 | 1.15e-04 | -1.18e-01 |
| KIRP | cg04872848 | chr14:75579200 | CGI:chr14:75578247-75578759 | promoter,exon,CDS,gene body | 2.88e-01 | 4.19e-01 | -4.35e+00 | 1.34e-05 | 4.76e-05 | -1.31e-01 |
| CHOL | cg26344619 | chr14:75579675 | CGI:chr14:75578247-75578759 | promoter,gene body | 5.26e-01 | 3.22e-01 | 2.21e+00 | 2.70e-02 | 3.50e-02 | 2.04e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| KIRC | cg04001333 | chr14:75579005 | CGI:chr14:75578247-75578759 | promoter,exon,CDS,gene body | 2.19e-01 | 3.23e-01 | -2.57e+00 | 1.01e-02 | 1.72e-02 | -1.04e-01 |
Top |
Exon skipping events with PSI in TCGA for FLVCR2 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for FLVCR2 |
| ∗Please access CAeditome for RNA editing annotation. |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for FLVCR2 |
| TFs related to FLVCR2. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| READ | ZNF235 | FLVCR2 | 4.42e+00 | 9.90e-01 | 3.09e+00 | 1.38e-03 | Male-biased |
| READ | ZNF287 | FLVCR2 | 4.26e+00 | 9.86e-01 | 3.05e+00 | 2.13e-03 | Male-biased |
| FLVCR2 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for FLVCR2 |
| RBPs related to ES in FLVCR2. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| FLVCR2 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
| ENSG00000119686 | DHRS4-AS1,hsa-mir-211,FLVCR2 | Male-specific ceRNA | TCGA-KIRP |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs60135526 | chr14:82925182:T:A | - | 0.256014217966583 | 0.0284878666216294 | GBM | Female-baised eQTL |
| rs12434899 | chr14:77063967:G:A | - | 0.414350525767042 | 0.00791909114538903 | KIRP | Female-baised eQTL |
| rs8014604 | chr14:77074512:T:C | - | 0.414140646783869 | 0.00800016410267621 | KIRP | Female-baised eQTL |
| rs17116744 | chr14:82426629:T:C | - | 0.354023675284527 | 0.0452441731880844 | KIRP | Female-baised eQTL |
| rs34354494 | chr14:84091924:G:A | - | 0.136685192999315 | 0.0303759828016765 | BLCA | Female-baised eQTL |
| rs12884245 | chr14:84103845:G:A | - | 0.134332858859918 | 0.047336564929315 | BLCA | Female-baised eQTL |
| rs138929720 | chr14:84099785:G:A | - | 0.134135193648064 | 0.048611725210379 | BLCA | Female-baised eQTL |
| rs55817768 | chr14:73580602:G:T | - | 0.137193098473943 | 0.0143136365911114 | COAD | Female-baised eQTL |
| rs111664109 | chr14:73578868:G:A | - | 0.137134892825046 | 0.0144703969992964 | COAD | Female-baised eQTL |
| rs112571112 | chr14:73579009:C:T | - | 0.137134892825046 | 0.0144703969992964 | COAD | Female-baised eQTL |
| rs57548703 | chr14:73580444:A:G | - | 0.137134892825046 | 0.0144703969992964 | COAD | Female-baised eQTL |
| rs11159152 | chr14:75815818:G:A | - | -0.117614053749062 | 0.037356710042135 | COAD | Female-baised eQTL |
| rs2113576 | chr14:75744488:T:C | - | -0.114631690014873 | 0.0442638437935184 | COAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs34844197 | chr14:78380295:G:A | - | 0.245859307173204 | 0.00180490305605817 | READ | Male-baised eQTL |
| rs34310902 | chr14:78381663:C:T | - | 0.220897910263341 | 0.00910955349411802 | READ | Male-baised eQTL |
| rs36096270 | chr14:78381986:T:C | - | 0.220897910263341 | 0.00910955349411802 | READ | Male-baised eQTL |
| rs34783487 | chr14:78394904:G:T | - | 0.201257625271341 | 0.0266601921170839 | READ | Male-baised eQTL |
| rs34598586 | chr14:78407866:C:T | - | 0.183063623381403 | 0.0450045855107347 | READ | Male-baised eQTL |
| rs12887878 | chr14:78404750:G:A | - | 0.181931239351002 | 0.049549004905433 | READ | Male-baised eQTL |
| rs177192 | chr14:78102085:A:C | - | -0.109918960144835 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs177191 | chr14:78102123:G:T | - | -0.109918960144835 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs177190 | chr14:78102181:T:C | - | -0.109918960144835 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs177189 | chr14:78102240:A:G | - | -0.109918960144835 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs78233581 | chr14:78102544:C:T | - | -0.109918960144835 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs177180 | chr14:78105149:C:T | - | -0.109918960144835 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs177170 | chr14:78106800:A:G | - | -0.109918960144835 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs177168 | chr14:78108034:T:C | - | -0.109918960144835 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs177159 | chr14:78112706:A:G | - | -0.109918960144835 | 0.00509353721594557 | SARC | Male-baised eQTL |
| rs177143 | chr14:78124465:G:A | - | -0.109799630984387 | 0.00531374010325674 | SARC | Male-baised eQTL |
| rs2371105 | chr14:79866759:A:T | - | -0.0921529869574557 | 0.0219634003299534 | SARC | Male-baised eQTL |
| rs1569333 | chr14:79867693:G:A | - | -0.0921529869574557 | 0.0219634003299534 | SARC | Male-baised eQTL |
| rs8022726 | chr14:79876085:G:T | - | -0.0890687795423437 | 0.0315118842018778 | SARC | Male-baised eQTL |
| rs2064002 | chr14:79876951:A:G | - | -0.0890687795423437 | 0.0315118842018778 | SARC | Male-baised eQTL |
| rs4558343 | chr14:79879355:G:T | - | -0.0890687795423437 | 0.0315118842018778 | SARC | Male-baised eQTL |
| rs10141936 | chr14:79880327:A:G | - | -0.0890687795423437 | 0.0315118842018778 | SARC | Male-baised eQTL |
| rs10220538 | chr14:79859102:T:C | - | -0.0896347701491135 | 0.0414472180039804 | SARC | Male-baised eQTL |
| rs11159423 | chr14:79875263:T:C | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs4899750 | chr14:79877401:T:G | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs5000630 | chr14:79877837:T:G | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs2064003 | chr14:79877936:G:A | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs10135705 | chr14:79878574:C:G | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs2064005 | chr14:79878777:A:G | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs12881175 | chr14:79880190:T:C | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs7142797 | chr14:79880468:C:T | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs1015024 | chr14:79881299:C:T | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs2078142 | chr14:79881685:C:T | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs2178887 | chr14:79881712:C:T | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs8017083 | chr14:79882487:C:T | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs8021467 | chr14:79882812:C:T | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs2205224 | chr14:79882989:A:C | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs994009 | chr14:79883235:T:A | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs2205225 | chr14:79883236:C:A | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs8018470 | chr14:79883775:T:G | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs5007586 | chr14:79884819:T:A | - | -0.0855663578589416 | 0.0479068299717561 | SARC | Male-baised eQTL |
| rs72718423 | chr14:65962603:G:A | - | 0.0886533278741265 | 0.0494144371211802 | SARC | Male-baised eQTL |
| rs8017398 | chr14:75751132:C:T | - | -0.0472393064838492 | 0.02774392251677 | LGG | Male-baised eQTL |
| rs10143491 | chr14:81654983:C:T | - | 0.0481450443783439 | 0.0368640709002674 | LGG | Male-baised eQTL |
| rs9323708 | chr14:81663371:A:G | - | -0.0480567804097651 | 0.038866969312522 | LGG | Male-baised eQTL |
| rs2371808 | chr14:81644837:G:A | - | 0.0469645018286937 | 0.0472334718158043 | LGG | Male-baised eQTL |
| rs11159509 | chr14:81645266:G:A | - | 0.0469645018286937 | 0.0472334718158043 | LGG | Male-baised eQTL |
| rs11159510 | chr14:81645601:G:C | - | 0.0467464260888443 | 0.0490320746709717 | LGG | Male-baised eQTL |
| rs6574782 | chr14:84328702:A:C | - | -0.0617893029230403 | 0.0167891445903594 | KIRC | Male-baised eQTL |
| rs4078112 | chr14:84329428:G:C | - | -0.0587533895903503 | 0.0256487228771341 | KIRC | Male-baised eQTL |
| rs11159648 | chr14:84326003:G:C | - | -0.056448951280112 | 0.0322934299404382 | KIRC | Male-baised eQTL |
| rs7151091 | chr14:67867432:C:T | - | 0.0519518418886943 | 0.0473803483720453 | BLCA | Male-baised eQTL |
| rs7494181 | chr14:65820987:T:C | - | -0.0890356802344898 | 0.000950160421477328 | LUAD | Male-baised eQTL |
| rs12893350 | chr14:71205678:A:T | - | 0.0588941394776551 | 0.0182814407875539 | LUAD | Male-baised eQTL |
| rs11158896 | chr14:71204416:C:T | - | 0.058449859710068 | 0.020034888393312 | LUAD | Male-baised eQTL |
| rs66549050 | chr14:71205083:T:C | - | 0.0582572736777034 | 0.0213062051500264 | LUAD | Male-baised eQTL |
| rs4902920 | chr14:71194995:A:G | - | 0.0551859526198753 | 0.0305946250158004 | LUAD | Male-baised eQTL |
| rs2057829 | chr14:71197099:G:A | - | 0.0554559614404103 | 0.0319015974517019 | LUAD | Male-baised eQTL |
| rs11628426 | chr14:71191366:A:T | - | 0.0546380249437234 | 0.033799431885257 | LUAD | Male-baised eQTL |
| rs4902919 | chr14:71194956:T:C | - | 0.0546150853740926 | 0.0349379149971781 | LUAD | Male-baised eQTL |
| rs11626311 | chr14:71190049:G:A | - | 0.0549104257486453 | 0.0354017820248947 | LUAD | Male-baised eQTL |
| rs4899389 | chr14:71201146:G:A | - | 0.0549225443171261 | 0.0365679363826303 | LUAD | Male-baised eQTL |
| rs11628388 | chr14:71191268:A:G | - | 0.0541856553296722 | 0.0387949230759589 | LUAD | Male-baised eQTL |
| rs2189799 | chr14:71190505:A:G | - | 0.0543589826057819 | 0.0389632897373682 | LUAD | Male-baised eQTL |
| rs4902914 | chr14:71185370:T:C | - | 0.0542935787934581 | 0.0392274552988553 | LUAD | Male-baised eQTL |
| rs117725299 | chr14:71964222:C:T | - | 0.0920206107530033 | 0.0464493463359633 | LUAD | Male-baised eQTL |
| rs758236 | chr14:71971181:A:T | - | -0.114290524439728 | 0.0133139427910685 | COAD | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000119686 |
| CpG Site: cg04872848 | |
| Position to Gene: gene,exon,CDS,promoter | |
| Male Effect: - | |
| Female Effect: -0.207896039670759 |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg04872848 | chr14:75579200 | gene,exon,CDS,promoter | -0.207896039670759 | 7.78743985999611e-05 | -0.314329384058316 | 2.9710744617376737e-07 | LUAD |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of FLVCR2 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
| ENSG00000119686 | FLVCR2 | C1856972 | Encephaloclastic Proliferative Vasculopathy | 1 | CTD_human |
